Hogan Lovells advises Soliton on its US$550 million acquisition by Allergan Aesthetics

Hogan Lovells advises Soliton on its US$550 million acquisition by Allergan Aesthetics

Press releases | 22 December 2021

Washington, D.C., 22 December 2021 – Global law firm Hogan Lovells advised medical device company Soliton, Inc. on its acquisition by Allergan Aesthetics, an AbbVie company, which was successfully completed on December 16. As part of the US$550 million deal, Allergan Aesthetics acquired Soliton's RESONIC, its Rapid Acoustic Pulse device. The deal was announced on May 10.

The RESONIC device initially received U.S. Food and Drug Administration 510(k) clearance for the short-term improvement in the appearance of cellulite, and that clearance has now been expanded to long-term improvement up to one year.

Read more on the deal here.

Soliton, Inc. has been a long-time client of Hogan Lovells through FDA medical device partner Janice Hogan (Philadelphia). The multi-office and multi-practice Hogan Lovells team was led by corporate M&A partners Joseph Gilligan and Les Reese, and included partners Brian O’Fahey, Carin Carithers, Jasper Howard, Joseph Krauss (all D.C.), and Steve Abrams and Janice Hogan (Philadelphia), counsel Robert Hayes, senior associates David Steenburg, Brendan Oldham, and Natalie Kone, and associates Curtis Victor and Bothwell Graham (all D.C.). Counsel was also provided by an antitrust team comprised of partner Lauren Battaglia, counsel Robert Baldwin, and associates Benjamin Sanchez and Meschelle Noble (all D.C.), and a litigation team led by partner William Regan, with senior associate Allison Wuertz, and associates Maura Allen and Peter Bautz (all New York). The team also included IP partner Robert Underwood in Boston and FDA medical device associate Erkang Ai in Philadelphia.